As shown in Table 1, reduction in steatosis, inflammation and fibrosis after RYGB are frequently reported, but four studies [38,43,44,49] described worsening of the degree of fibrosis in a few cases.

Increased total numbers of macrophages and 'M1' or 'classically activated' macrophages are present in the adipose tissue of obese insulin-resistant individuals, and these are thought to be the ...

TEL AVIV, Israel, June 12, 2018 /PRNewswire/ --Statistically significant reduction in liver fat was demonstrated by Magnetic Resonance Spectroscop ...

Pegbelfermin was safe and effective in improving markers of steatosis, fibrosis and inflammation among patients with nonalcoholic steatohepatitis with stage 3 fibrosis, according to a presentation ...

In multiple animal models, Aramchol has been effective in three key pathologies of NASH: steatosis, inflammation, and fibrosis. In recent news, Galmed released encouraging top-line results on June ...

Conatus is expected to report top line data readouts for emricasan in Phase 2b clinical trials, NASH severe Portal Hypertension, decompensated NASH cirrhosis, and NASH fibrosis, the focus of this ...

“A phase 1b-2a study involving patients with NASH did not show safety concerns and suggested that pegozafermin therapy may improve hepatic steatosis, markers of inflammation and fibrosis ...

--Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the National Medical Products Administration has ...

Nonalcoholic steatohepatitis (NASH), characterized by liver steatosis, inflammation and injury, has emerged as one of major causes for end-stage liver disease like hepatocellular carcinoma.

The assessment of the genetic contribution to fibrosis in NASH ... all organs which lack the parenchymal pathology of NASH, such as steatosis. ... where fibrosis is typically driven by inflammation.